ARGX vs. NTRA: argenx vs. Natera Stock Comparison
How do argenx (ARGX) and Natera (NTRA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
argenx (ARGX) and Natera (NTRA) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Natera (NTRA) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ARGX | NTRA |
|---|---|---|
| Name | argenx SE American Depositary Receipt | Natera, Inc. |
| Country/Region | Netherlands | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 58.31 billion USD | 45.05 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | May 18, 2017 | July 1, 2015 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ARGX | NTRA |
|---|---|---|
| Total Return (1Y) | 11.91% | 61.03% |
| Total Return (3Y, Annualized) | 25.68% | 92.02% |
| Total Return (5Y, Annualized) | 24.22% | 23.20% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Natera (NTRA) has an aggressive beta of 1.58, indicating higher sensitivity to broad-market moves, while argenx (ARGX) is defensive at 0.45 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.
| Metric | ARGX | NTRA |
|---|---|---|
| Volatility (1Y, Annualized) | 37.87% | 52.30% |
| Beta (5Y) | 0.45 | 1.58 |
| Max Drawdown (5Y) | -38.20% | -75.72% |
| Avg. Volume (3M) | 359.84K | 1.68M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ARGX | NTRA |
|---|---|---|
| Sharpe Ratio (1Y) | 0.20 | 1.09 |
| Sortino Ratio (1Y) | 0.31 | 1.63 |
Profitability
ROE (TTM)
argenx (ARGX) has no ROE value reported for this period; Natera (NTRA) reports a negative figure of -10.55%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ARGX
- --
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-10.55%
- Max
- 109.18%
- Q3
- 6.23%
- NTRA
- -10.55%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Natera (NTRA) reports a negative net margin of -5.66%, usually indicating a net loss over the period. Meanwhile argenx (ARGX) reports 31.73%, ranking against industry peers normally.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.73%
- ARGX
- 31.73%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-5.66%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- NTRA
- -5.66%
- Min
- -17.05%
Operating Margin (TTM)
Natera (NTRA) reports a negative operating margin of -7.64%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile argenx (ARGX) reports 36.27%, ranking against industry peers normally.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.27%
- Max
- 83.12%
- ARGX
- 36.27%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-7.64%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- NTRA
- -7.64%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ARGX | NTRA |
|---|---|---|
| ROE (TTM) | -- | -10.55% |
| ROA (TTM) | -- | -6.79% |
| Net Margin (TTM) | 31.73% | -5.66% |
| Operating Margin (TTM) | 36.27% | -7.64% |
| Gross Margin (TTM) | 59.84% | 65.14% |
Growth
Revenue Growth
argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Natera (NTRA) at 35.90% is closer to the peer norm — faster top-line expansion for ARGX.
EPS Growth
Only one side can be read here: argenx (ARGX) reports EPS growth of 53.13%, ranked against its industry; Natera (NTRA) has no EPS growth figure this period.
Growth Metrics
| Metric | ARGX | NTRA |
|---|---|---|
| Revenue Growth (YoY) | 89.64% | 35.90% |
| Revenue Growth (3Y CAGR) | 116.25% | 41.14% |
| EPS Growth (YoY) | 53.13% | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Natera (NTRA) shows current ratio of 2.81 against its industry benchmark, while argenx (ARGX) has no reading this period.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ARGX
- --
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.81
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- NTRA
- 2.81
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
argenx (ARGX) at 0.01 keeps leverage in the lower industry quartile, while Natera (NTRA) at 0.13 runs a more typical debt-to-equity mix.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- ARGX
- 0.01
- Min
- 0.00
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NTRA
- 0.13
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ARGX | NTRA |
|---|---|---|
| Current Ratio (MRQ) | -- | 2.81 |
| Debt / Equity (MRQ) | 0.01 | 0.13 |
| Net Debt / EBITDA | -2.70 | -- |
Dividends
Dividend Yield (TTM)
Neither argenx (ARGX) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither argenx (ARGX) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ARGX | NTRA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: argenx (ARGX) trades at 32.12 times trailing earnings, ranked against its peers, while Natera (NTRA) has no P/E ratio this period.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.12
- Max
- 85.34
- Q3
- 43.46
- ARGX
- 32.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- NTRA
- --
P/S Ratio (TTM)
On P/S ratio, both argenx (ARGX) at 9.86 and Natera (NTRA) at 15.49 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.86
- Max
- 58.18
- Q3
- 25.77
- ARGX
- 9.86
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.49
- Max
- 58.18
- Q3
- 25.77
- NTRA
- 15.49
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Measured against book value, both argenx (ARGX) at 172.23 and Natera (NTRA) at 23.99 look expensive — each P/B ratio sits above its industry’s benchmark range.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
172.23
- ARGX
- 172.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.99
- NTRA
- 23.99
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ARGX | NTRA |
|---|---|---|
| P/E Ratio (TTM) | 32.12 | -- |
| P/S Ratio (TTM) | 9.86 | 15.49 |
| P/B Ratio (MRQ) | 172.23 | 23.99 |
| Free Cash Flow Yield (TTM) | -- | 0.19% |